updat outlook follow recent event includ new guidanc
follow otezla deal close expect revenu vs
prior adj ep vs prior new analysi
repatha fourier cv-outcom studi present aha show risk-
reduct patient treat within year post-mi patient
distant mi cosmic-hf new result present aha show addit
increas systol function omecamtiv mecarbil chang show
consist improv diastol function mdco full
result impli long-term mace reduct nv takeout support
potenti inhibitor updat model reflect event drive
issu new guidanc follow close otezla acquisit includ
expect revenu vs prior adj ep
vs prior expect otezla grow next
year driven volum new indic new market ad addit
otezla model add increment revenu
new analysi fourier cv-outcom studi present aha show
patient experienc mi ago higher risk
subsequ cv-event heart attack stroke cv-death risk-reduct
repatha vs patient mi ago risk-reduct
addit analysi also show impact ldl-c lower cognit
cosmic-hf new result present aha show hfref patient
receiv omecamtiv mecarbil systol eject time increas expect
diastol fill time reduc diastol paramet worsen e-
wave veloc e/a-ratio e/e significantli chang vs placebo
galactic-hf enrol complet increas po estim
omecamtiv prior
mdco full result aha show signific durabl
ldl-c reduct inclisiran mdco updat expect
cv-outcom studi pool data impli
mace risk-reduct base nv takeout mdco suspect grow
optim ldl-c reduct therapi given increas evid cv-outcom
improv believ dynam provid posit read across repatha
updat model reflect otezla deal close encourag
aha data bolster repatha market potenti also continu view
differenti pipelin driver addit margin expans unlock
signific sharehold valu driven financi disciplin manag
biotechnolog
discov
develop manufactur market
cancer autoimmun
diseas specialti market
year price histori
analyst certif import disclosur see disclosur
estim amgen top line remain rel stabl
margin improv sg decreas
percentag sale expect volum increas growth
product continu increas market penetr pipelin
estim revenu remain rel flat
next year margin continu expand
manag track record financi disciplin
top line believ posit maintain long-term
revenu stabil matur product declin new product
continu grow pipelin deliv steadi flow new
product addit offer dividend yield
believ provid valuat support
updat data kra inhibitor major
updat data bcma bite
data bcma hle bite
data bite
estim sell price two experiment product
low price increas exist product would
meaning upsid earn estim
experiment compound launch sooner
estim would result addit upsid estim
repatha growth slow pipelin asset fail launch
estim gradual declin revenu ep scenario
estim stock could valu rang
next month
price target base dcf valuat assum wacc residu growth rate
due declin in-lin product off-set new product pipelin long term see top line essenti stabl
forecast peak sale tezepelumab base probabl success base probabl
success omecamtiv base probabl success
believ greatest risk stock next five year disrupt continu success repatha fda
approv experiment therapi romosozumab continu success launch aimovig migrain biosimilar abp abp
abp key risk project would occur repatha growth slow experiment therapi biosimilar fail
launch
